Neurosense Therapeutics Ltd. · NASDAQ:NRSN
Neurosense Therapeutics — Investor Presentation (January 2024)
33 slides from Neurosense Therapeutics's investor presentation, Jan 9, 2024
Slide 1: Nasdaq: NRSN
Nasdaq: NRSN
Slide 2: Forward-Looking Statements
NeuroSense Therapeutics Nasdaq: NRSN Forward-Looking Statements This presentation and oral statements made regarding the subject of this presentation contain "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 that involve substantial risks an
Slide 3: NeuroSense Highlights
“¥ NeuroSense Highlights Developing novel Significant top line results from therapies for Phase 2b study for ALS" neurodegenerative Additional catalysts expected: diseases of high unmet Neurofilament results need (Jan 2024) Biomarker results (H1 2024) *ALS- Amyotrophic Lateral Sclerosis, also referr
Slide 4: Focused Pipeline
NeuroSense Therapeutics . %. Nasdaq: NRSN Focused Pipeline ‘, Diseases with Limited Treatment Options and High Commercial Opportunity =D I A A A AL ALS (7) (v) (Vy (<) + N#L' (Jan, 2024) + Biomarker data (Ht 2024) Alzheimer’s (v) (v) (V} e + Completion of Phase 2 enrollment (H2 2024) + Exploring pot
Slide 5: ALS
ALS is an incurable neurodegenerative disease, causing complete paralysis +5,000 and ultimately death New cases of ALS within 2-5 years from each year (US)' diagnosis ~$3B Annual Market Opportunity? Johns Hopkin Projected incre se in amyotrophic lateral sclerosis from 2015 to 2040, Nature Communicat
Slide 6: A Unique Synergistic Formulation With A Powerful Outcome
NeuroSense A Unique Synergistic Formulation With A | ss Powerful Outcome PrimeC is a novel formulation, consisting of specific doses of two FDA-approved drugs, designed to work synergistically on more than one target in ALS PrimeC & Celecoxib -an NSAID which reduces: Neuroinflammation © ° Glutamate
Slide 7: Synergistic Benefit: In-Vitro & In-Vivo
NeuroSense _Synergistic Benefit: In-Vitro & In-Vivo adage Nasdaq: NSN Synergistic Mode of Action Improved Pharmacokinetic (PK) Profile Male Mouse Brain PK Comparison Cipro vs. Combo i) a Passive Diffusion — Ciprofloxacin+Celecoxil — Ciprofloxacin Concentration (ng/ml) 00s 2 4 6 Time (h) This finding
Slide 8: PrimeC Demonstrated Statistically Significant Efficacy in Key Pre-Clinical Study
PrimeC Demonstrated Statistically Significant ‘Efficacy in Key Pre-Clinical Study “e, Studies were conducted in the laboratory of Dr. Justin Ichida, University of Southern California, using an “(7 induced Pluripotent Stem Cell (iPSC) Model Generated from People Living with ALS NeuroSense Nasdaq: NSN
Slide 9: PrimeC Unique Formulation Induces a Synchronized PK Profile
NeuroSense Therapeutics PrimeC Unique Formulation Induces a Sasdag:NRSN Synchronized PK Profile Seon: Synchronized = : Ref ciprofloxacin S So fitactts 2 5 Sera ro g 2 & PK profile studies in humans Time (h) Asynchronized PK profile of the two compounds, potentially maximizes the synergy between them
Slide 10: PrimeC Met Primary Endpoints and Exploratory Endpoints in Phase 2a Study
NeuroSense Therapeutics + PrimeC Met Primary Endpoints and Nasdag: NSN Exploratory Endpoints in Phase 2a Study NSToo2 15 patients Open-Label eee an or Well tolerated, no Reduced functional Significant changes in Primec drug related SAEs and respiratory ALS-related deterioration biomarkers s2-month d
Slide 11: PrimeC Phase 2b Trial Design
NeuroSense Therapeutics +} Nasdaq: NRSN PrimeC Phase 2b Trial Design , Randomized, Prospective, Double-Blind, Placebo-Controlled Study GYorrocm Double Blind - 6 Months (N=68) Open Label Extension ‘2 Months ~90% of patients in Primec and Placebo groups were cottreated with Riluzole PrimeC (N=45) Scre
Slide 12: PrimeC Phase 2b Trial Endpoints
NeuroSense PrimeC Phase 2b Trial Endpoints —. @ Primary Endpoints + Safety and Tolerability Measures + ALS-Hallmark Biomarker Measures of TDP-43 and ProstaglandinJ2 (results expected H1 2024) (2) Secondary Efficacy Endpoints + ALSFRS-R (ALS Functional Rating Scale) + SVC (Slow Vital Capacity) + Surv
Slide 13: PrimeC Phase 2b Study ITT and PP Pre-specified Analyses
NeuroSense PrimeC Phase 2b Study Therapeutics Nasdaq: NRSN ITT and PP Pre-specified Analyses & Analysis Intent to Treat (ITT) and Per Protocol (PP) are Pre-defined populations both pre-specified analyses within the study a PP ITT assesses the effect of the treatment on all (w=68) (N-62) patients enr
Slide 14: PrimeC Phase 2b Study Inclusions / Exclusions
PrimeC Phase 2b Study Inclusions / Exclusions Inclusion Criteria + Males or females between the ages of 18 and 75 years of age + Diagnosis of familial or sporadic ALS * Disease duration less than 30 months prior to screening * Pre-enrollment ALSFRS-R slope from disease onset 2 0.3 points per month *
Slide 15: PrimeC Phase 2b Study: Well Balanced Enrollment
PrimeC Phase 2b Study: Well Balanced Enrollment Primec Placebo n=45, n=23 Male 60.0% 60.9% Female 40.0% 39.1% Age 594 54.9 Height (cm) 170.8 171.2 Weight (kg) 70.6 A BMI (kg/m2) 244 24.0 TRICALS Risk Profile “4.2 “404 Patients on background ALS therapy 1% 87% PP Analysis (PrimeC=43; Placebo=19) ALSF
Slide 16: PrimeC Phase 2b Study Results: Safety and Tolerability
PrimeC Phase 2b Study Results Achieved Primary Endpoints with a Safety and Tolerability Profile Comparable to Placebo [Adverse Events (AE) HTreatment-Emergent AEs (TEAE) Study Drug Related Treatment-Emergent AEs (TEAE) Serious Treatment-Emergent AEs (TEAE) [Subject death HTEAE leading to Study Drug
Slide 17: Phase 2b Results: PrimeC Attenuated Disease Progression by 37% in ALSFRS-R
Phase 2b Study Results — Per Protocol Population Analysis Berta ~~ PrimeC Significantly Attenuated = Borsvoiem _ Disease Progression by 37% in ALSFRS-R (p=0.03) 40 *—— Double- Blind Period 2 8 —® PrimeC ra Placebs ra - % 35 jacebo 2 £ 3 = % g 37.4 3 30 Fpetesoos T T T T Baseline 60 120 180 Days from
Slide 18: Losing or Keeping a Single Point On the ALSFRS-R May Have a Significant Impact
NeuroSense Therapeutic Losing or Keeping a Single Point On the ALSFRS-R May Have a ssdaa:nasw PARADIGM Significant Impact ‘A wpoint decrease in the hands' Functional Loss Score can represent a transition from ae independent feeding to requiring assistance. i@ cs A tpoint stumble in the legs can be t
Slide 19: PrimeC Slowed the Loss of Physical Functions vs Placebo
NeuroSense Phase 2b Study Results — Per Protocol Population Analysis zee Nasdaq: NRSN PrimeC Slowed the Loss of Physical Functions vs Placebo Bow ALSFRS-R Total Score Wl Placebo Mean ALSFRS-R total score was 3.22 points higher at 6 months for PrimeC & primec : compared to placebo i ga é 2 > 3-22 Poi
Slide 20: PrimeC Slowed the Loss of Physical Functions vs Placebo by Domain
: 5 NeuroSense Phase 2b Study Results — Per Protocol Population Analysis Therapeutics Nasdaq: NRSN PrimeC Slowed the Loss of Physical Functions vs Placebo & Bulbar Respiratory Background Ba 28 g Respiratory failure i eon Ee is the most common ga fa] cause of death from g i ALS Bs bs Fine Motor Gross
Slide 21: PrimeC Attenuated Slow Vital Capacity (SVC) by 17.2%
NeuroSense Therapeutics “= Phase 2b Study Results - Per Protocol Population Analysis Nasdaq: NRSN PrimeC Attenuated Slow Vital Capacity (SVC) by 17.2% BGersnoiem 3 38 Double- Blind Period ———— 2 8 -® Primec -® Placebo x 3 1 17.2% pralue=0.39 predicted SVC Score (%) % g 2 ry T T T T Baseline 60 120 1
Slide 22: Pioneering Approach to ALS Biomarker Research
Pioneering Approach to ALS Biomarker Research wos To Maximize Clinical Efforts NeuroSense is collaborating with leading KOLs and industry on the PARADIGM trial to elucidate PrimeC’s MOA via novel methodologies AS Ce. incviv, ¢=" e090 * Biogen i)
Slide 23: Proven Success of Combined Therapy
NeuroSense Proven Success of Combined Therapy Sasdag: ESN Case Study: Amylyx (NASDAQ: AMLX) Market Cap: ~ $1 B (Jan 2024) ion Therapy of generic + supplement 158,000/ year Estimated 2026 Sales: $1.1B/ The FDA approved Amylyx’s drug, AMX0035 (Relyvrio?), in 2 clinical trial attenuated di arc Goodman
Slide 24: PrimeC: Strong Clinical and Commercial Potential
*Primec: Strong Clinical and Commercial Potential NeuroSense Sitemap € Ut iC.S == NeuroSense Therapeutics Nasdaq: NRSN Novel combination therapy candidate of approved products optimized for PK and synergistic effects to address ALS and potentially other disease targets Robust clinical efficacy and e
Slide 25: Alzheimer's Studies Reveal Potential Effect of NeuroSense's Combination Therapy
Alzheimer’s (AD) Studies Reveal Potential faa Nasdaq: NSN Effect of NeuroSense’s Combination Therapy @ om * * 200 . bs = ae 1500- = u =“ as ie 2 2. 1000 20 Es a Biomarkers tested in Neuronal ae Derived Exosomes ° . . comparing non-treated Healthy Cont > Cont, aD Conus ab 4 7 ae vs. AD patients, to e
Slide 26: AD Phase 2 Study Design
AD Phase 2 Study Design Randomized, Prospective, Double-Blind, Placebo-Controlled Study €& RoAD i 20 patients with mild to moderate AD 11 me to aaaad © (0) Cognic- intermediate formulation (=Primec - ER) t2-month dosing Primary Endpoint Safety Secondary Efficacy Clinic visit every 3 months & Tolerab
Slide 27: Exceptional Scientific Advisory Board
Exceptional Scientific Advisory Board NeuroSense Therapeutics Nasdaq: NRSN Prof. Jeremy Shefner (Chair) Senior Vice President at the Barrow, Neurological Institute Chair of the Department of Neurology N NEALS Prof. Orla Hardiman Head of Academic Unit of Neurology at Trinity College Dublin and Consul
Slide 28: Key Collaborations
Key Collaborations HARVARD OLN MEBIGhL SCHOOL GENERAL HOSPITAL © NeuraLight Quantalx Neuroscience. sug UMC Utrecht i? USC IsrA. L.S ae rons €Q NeuroSense 600 TEL AVIV UNIVERSITY ASSOCIATION
Slide 29: Milestones Achieved and Upcoming Potential Catalysts
NeuroSense Therapeutics Milestones Achieved and wasdag; NSN Upcoming Potential Catalysts 2023, 2024 Completed Alzheimer’s biomarker study with positive results 6 © Initiated ALS Phase 2b PARADIGM Neurofilament Results study Completed Parkinson’s biomarker ° Biomarker Results study with positive resu
Slide 30: For more information
NeuroSense Therapeutics Nasdaq: NRSN For more information:
Slide 31: Phase 2b Study Results — Intent to Treat Analysis
NeuroSense Phase 2b Study Results — Intent to Treat Analysis Therapeutics PrimeC Attenuated Disease Progression By 29.2% Gon _ Difference in ALSFRS-R Adjusted ALSFRS-R Total Score eg 8 -® PrimeC (N=45) col ™ -® Placebo (N=23) © F 35. a d [4 T I + g I z 29.2% 3 30 p-value= 0.12 g g es < T T T T Basel
Slide 32: Slow Vital Capacity: 13.3% Decrease in Patients Treated with PrimeC vs Placebo
Phase 2b Study Results — Intent to Treat Analysis Slow Vital Capacity (SVC): Observed a 13.3% Decrease in Patients treated with PrimeC vs Placebo Adjusted Predicted SVC (%) 100 90 80 70 60 Adjusted Predicted SVC (%) -® PrimeC (N=45) —™ Placebo (N=23) 13.3% T T T . Baseline 60 120 180 Days from basel
Slide 33: PrimeC Slowed the Loss of Physical Function vs. Placebo at 6-months
~~ PrimeC Slowed the Loss of Physical Function vs. Nasdag: NRSN Placebo at 6-months Borsvoicm Tntontion Fo Treat (FA Por Provecol (FF) 32.09 29.862 yess 29.295 RLSERS-R Total Score 130.206, # (27-424, 130.606, 17 126.742, Suoa | 32c30nr Se See) Se8Kai 10.272 9.0 0.502 aber Domain seore || a0 ' t o.2
NeuroSense Therapeutics — Investor Presentation (January 2024) on 6ix